Elite Pharmaceuticals reports positive bioequivalence study results for generic anticonvulsant

Elite Pharmaceuticals announced positive results from a pivotal bioequivalence study for an undisclosed anticonvulsant generic drug, with the generic product demonstrated as bioequivalent to the branded product. The company plans to file an Abbreviated New Drug Application with the FDA, potentially addressing a $840 million market opportunity identified by IQVIA.